These are top 10 stocks traded on the Robinhood UK platform in July
Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,092 shares of common stock on July 28, 2025, at a price of $139.8083, for a total of $851,712. The transaction comes as the $19.2 billion molecular diagnostics company maintains a strong financial health score according to InvestingPro data, with a comfortable current ratio of 3.87x and impressive revenue growth of 51.5% in the last twelve months.
Following the transaction, Chapman directly owns 169,400 shares of Natera.
The sale was to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs) and was executed under a pre-arranged trading plan that complies with Rule 10b5-1(c).
In other recent news, Natera has reported significant developments that are likely to interest investors. RBC Capital Markets has maintained an Outperform rating for Natera, with a price target of $251, citing strong first-quarter performance and increased guidance due to accelerated revenue growth. This optimism is echoed by TD Cowen, which raised its price target for Natera to $200, noting that the company’s sales were 13% higher than expected. Natera’s Signatera product has shown remarkable growth, with clinical volumes increasing by 52% year-over-year, reaching approximately 17,000 in the first quarter.
Medicare has expanded coverage for Natera’s Signatera MRD assay, now including a broader range of cancers. This follows a pan-cancer study presented at the 2025 American Society of Clinical Oncology Annual Meeting, which highlighted the assay’s clinical utility. Leerink Partners also reiterated an Outperform rating with a $220 price target, underscoring the importance of the recent Medicare coverage decision for Natera’s WGS Signatera assay. Evercore ISI initiated coverage on Natera with an Outperform rating and a price target of $170, suggesting potential upside. These developments collectively reflect a positive outlook for Natera, as supported by multiple analyst endorsements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.